Perspective Therapeutics (CATX) said Monday the first patient was dosed in a new cohort of its phase 1/2a trial evaluating the safety of targeted alpha-particle therapy [212Pb]VMT01 in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans.
Patients in the new cohort are receiving the therapy in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb (BMY) as Opdivo, compared to earlier cohorts where the patients received it as monotherapy, the company said.
The data from this part of the study will enable the company to further understand "how lower-dose radiopharmaceuticals can be optimized in combination with immunotherapies," Perspective CEO Thijs Spoor said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。